[UPDATE] Ordinary Index Rebalancing in the Solactive Pharma Breakthrough Value Index | March 2022

In the ordinary rebalance the following composition will be implemented effective open 21.03.2022:

ABBVIE INC
ALNYLAM PHARMACEUTICALS INC
AMRYT PHARMA LTD – SPNR ADR
BIOGEN INC
BIOMARIN PHARMACEUTICAL INC
BRISTOL-MYERS SQUIBB CO
CHUGAI PHARMACEUTICAL CO LTD ORD
CLINUVEL PHARMACEUTICALS LTD
CSL LTD ORD
CTI BIOPHARMA CORP
EMERGENT BIOSOLUTIONS INC
GENMAB A/S
GRIFOLS SA CLASS A
HALOZYME THERAPEUTICS INC
HORIZON THERAPEUTICS PLC
INCYTE CORP
IONIS PHARMACEUTICALS INC
IPSEN SA
JAZZ PHARMACEUTICALS PLC
JOHNSON & JOHNSON
KYOWA KIRIN CO LTD
NEKTAR THERAPEUTICS
NIPPON SHINYAKU CO LTD
NOVARTIS AG-ADR
OXFORD BIOMEDICA PLC
PHARMA MAR SA
PTC THERAPEUTICS INC
ROCHE HOLDING AG
SAREPTA THERAPEUTICS INC
SINO BIOPHARMACEUTICAL LTD ORD
SWEDISH ORPHAN BIOVITRUM AB
ULTRAGENYX PHARMACEUTICAL INC
UNITED THERAPEUTICS CORP
VERTEX PHARMACEUTICALS INC